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OBJECTIVES The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analogue
beraprost sodium during a 12-month double-blind, randomized, placebo-controlled trial in
patients with pulmonary arterial hypertension (PAH).
BACKGROUND Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart
failure and death. Despite the risks from its delivery system, continuous intravenous
epoprostenol remains the most efficacious treatment currently available.
METHODS A total of 116 patients with World Health Organization (WHO) functional class II or III
primary pulmonary hypertension or PAH related to either collagen vascular diseases or
congenital systemic to pulmonary shunts were enrolled. Patients were randomized to receive
the maximal tolerated dose of beraprost sodium (median dose 120 g four times a day) or
placebo for 12 months. The primary end point was disease progression; i.e., death,
transplantation, epoprostenol rescue, or 25% decrease in peak oxygen consumption (VO2).
Secondary end points included exercise capacity assessed by 6-min walk test and peak VO2,
Borg dyspnea score, hemodynamics, symptoms of PAH, and quality of life.
RESULTS Patients treated with beraprost exhibited less evidence of disease progression at six months
(p  0.002), but this effect was not evident at either shorter or longer follow-up intervals.
Similarly, beraprost-treated patients had improved 6-min walk distance at 3 months by 22 m
from baseline and at 6 months by 31 m (p  0.010 and 0.016, respectively) compared with
placebo, but not at either 9 or 12 months. Drug-related adverse events were common and
were related to the disease and/or expected prostacyclin adverse events.
CONCLUSIONS These data suggest that beneficial effects may occur during early phases of treatment with
beraprost in WHO functional class II or III patients but that this effect attenuates with
time. (J Am Coll Cardiol 2003;41:2119–25) © 2003 by the American College of
Cardiology Foundation
Despite recent therapeutic advances, pulmonary arterial
hypertension (PAH) remains a life-threatening disorder
(1–3). Continuous intravenous infusion of epoprostenol
sodium (prostacyclin) improves exercise capacity, hemody-
See page 2126
namics, and quality of life in patients with primary pulmo-
nary hypertension (PPH) and in those with PAH related to
collagen vascular diseases, congenital systemic to pulmonary
shunts, or human immunodeficiency virus infection (4–12).
In addition, improved survival with epoprostenol has been
demonstrated in patients with severe PPH (4,5). Serious
complications, however, are associated with the use of
epoprostenol due in part to its short half-life (approximately
3 min) requiring a continuous intravenous infusion (4–7,12).
Thus, alternative routes of delivery of prostacyclin are being
investigated using stable prostacyclin analogues adminis-
tered orally, subcutaneously, or by inhalation (13–19).
Although beraprost sodium, a chemically stable and orally
active prostacyclin analogue, has similar pharmacologic
properties to epoprostenol, its half-life is significantly longer
(20–26). Several uncontrolled studies in patients with PAH
have reported improved exercise capacity, hemodynamics,
and survival with chronic beraprost (13–15). Furthermore, a
recently reported randomized, double-blind, placebo-
controlled, multicenter study showed improved exercise
endurance, i.e., 6-min walk distance, and symptoms after 12
weeks of beraprost treatment in World Health Organiza-
tion (WHO) functional class II and III PAH patients (27),
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i.e., treatment effect 25 m overall and 46 m in the subgroup
of patients with PPH.
The current multicenter, double-blind, randomized,
placebo-controlled study was designed to assess the effect of
beraprost on disease progression over a 12-month treatment
period in patients with WHO functional class II or III
PAH, and to evaluate the effects of beraprost on exercise
capacity, hemodynamics, signs and symptoms of PAH, and
quality of life.
METHODS
Selection of patients. Patients eligible for this study were
males or females over eight years of age with PAH in WHO
functional classes II or III, including PPH, and PAH
related to collagen vascular diseases or congenital systemic
to pulmonary shunts, despite treatment with anticoagulant
drugs, vasodilators (other than prostanoids or endothelin
receptor antagonists), diuretics, cardiac glycosides, or sup-
plemental oxygen. The inclusion criteria were a baseline
peak oxygen consumption (VO2) during exercise between 8
and 28 ml/kg/min determined during upright cycle ergom-
etry (actual range for inclusion varied based on age and
gender), a resting mean pulmonary artery pressure 25 mm
Hg, with mean pulmonary capillary wedge pressure of 15
mm Hg and pulmonary vascular resistance 3 U. Patients
were excluded if they had started or stopped any PAH
therapy within one month before screening.
The study was conducted in accordance with Good
Clinical Practices, the current version of the Declaration of
Helsinki and with local institutional regulations. The local
ethics review committee approved the protocol, and written
informed consent was obtained from all patients.
Study design. The study was designed as a double-blind,
randomized, placebo-controlled trial and was conducted in
10 centers in the U.S. All 116 patients were randomly
assigned to receive one tablet (20 g) of beraprost sodium or
matching placebo (United Therapeutics Corporation, Re-
search Triangle Park, North Carolina) four times daily
(QID) with meals for the first two weeks, and the dose was
increased by 20 g or matching placebo QID with meals
every two weeks, based on increasing signs, symptoms, and
tolerability. The maximal dose allowed in the study was 200
g QID. Side effects limiting dose increase were flushing,
headache, jaw pain, and diarrhea. Patients were eligible for
an open label continuation protocol with beraprost if they
completed the month 12 visit or withdrew from the study
because of a25% decrease in peak VO2 and were receiving
placebo.
Outcome measures. Patients were evaluated at baseline
and after 3, 6, 9, and 12 months of treatment with study
drug. The primary efficacy measure was a combined end
point of disease progression, defined as either the occurrence
of death, transplantation, initiation of chronic intravenous
epoprostenol or other chronic prostacyclin analogue therapy
(“rescue therapy”), or a 25% decrease in peak VO2 during
exercise from baseline. The secondary measures of efficacy
were the change from baseline to months 3, 6, 9, and 12 of
exercise endurance (6-min walk distance), the Borg dyspnea
score (a measure of perceived maximal breathlessness during
the 6-min walk test on a scale of 0 to 10, with higher values
indicating more severe dyspnea that is assessed immediately
after completion of the 6-min walk test), exercise tolerance
assessed by gas exchange (at rest and during exercise), signs
and symptoms of PAH, and quality of life (global, physical,
and emotional) as assessed by using the Minnesota Living
with Heart Failure Questionnaire (28). Cardiopulmonary
hemodynamics (at rest) were assessed at baseline and at the
end of study assessment for patients who completed the
study. Safety was assessed on the basis of recorded adverse
events, laboratory measures, and electrocardiography.
Patients underwent cardiopulmonary testing on an up-
right cycle ergometer (to maximum tolerated exercise level).
Gas exchange measurements were obtained throughout the
baseline rest, exercise, and early recovery periods. With the
patient in the upright position, while breathing room air
through a low deadspace mask, minute ventilation, exhaled
gas composition, systemic arterial blood pressure, and heart
rate were continuously measured. The arterial pressures,
heart rate, and gas exchange were recorded on a strip chart
recorder and a computer. Peak VO2, anaerobic threshold,
peak O2 pulse (VO2/heart rate), and the aerobic response to
the imposed work rate (VO2/work rate) were determined.
In addition, the ventilatory equivalent for CO2 was deter-
mined (VE/VCO2, where VE  minute ventilation and
VCO2  minute CO2 output). The peak VO2 data were
calculated from mean values from two separate cycle ergom-
etry tests performed within seven days of each other at each
assessment period. The cycle ergometry and 6-min walk
tests were administered by a trained tester not involved in
the patient’s daily care and unaware of the patient’s treat-
ment assignment.
Statistical analysis. The data were retained and analyzed
by the sponsor, United Therapeutics Corporation. The
sample size was estimated under the assumptions of a
two-sided alpha probability of 0.05, 80% power, and a
relative reduction of 50% in disease progression in the
beraprost group progression from a 50% incidence in the
placebo group (i.e., 50% to 25% incidence from the placebo
to beraprost treatment groups). Under these conditions, the
study’s 1:1 randomization required a sample size of 116
patients (58 per group).
Abbreviations and Acronyms
PAH  pulmonary arterial hypertension
PPH  primary pulmonary hypertension
QID  four times daily
VCO2  minute CO2 output
VE  minute ventilation
VE/VCO2  ventilatory equivalent for CO2
VO2  oxygen consumption
WHO  World Health Organization
2120 Barst et al. JACC Vol. 41, No. 12, 2003
Beraprost Therapy for PAH June 18, 2003:2119–25
Analysis was performed in the intent to treat population
that included all patients who were randomized and received
at least one dose of study drug. Data are presented as either
medians or mean  SEM. A value of p  0.05 was
considered statistically significant.
At the time of this study, the sponsor was also conducting
a study of beraprost in patients with intermittent claudica-
tion. The claudication study was unblinded, and beraprost
was shown to provide no benefit to patients with claudica-
tion, relative to placebo. Given the lack of efficacy and
concerns of equipoise, a decision was made by the sponsor
to terminate this study early to accelerate data review so as
not to withhold other PAH therapies with proven efficacy.
Because of the accelerated data review, changes from base-
line to month 9 were used as the primary analysis for all
efficacy measures. Patients may not have completed the
study through the month 9 assessment for the following
reasons: death, transplantation, clinical deterioration requir-
ing rescue therapy, decrease of more than 25% from baseline
in peak VO2, withdrawal of consent, adverse event (other
than that related to clinical deterioration of PAH), protocol
violation, or lost to follow-up.
Patients who discontinued as a result of death, transplan-
tation, rescue therapy owing to clinical deterioration, a
decrease in peak VO2 by more than 25% from baseline, or
who were too critically ill to complete their final exercise
assessment were analyzed as treatment failures. For the
primary end point, these events were counted as disease
progression events at the time of their discontinuation. For
secondary efficacy end points, worst rank was assigned for
nonparametric analyses, and a value corresponding to the
worst relative change from baseline observed among all
non-missing observations was assigned for parametric anal-
yses.
Patients who discontinued or had missing assessments for
any other reason, i.e., discontinuation due to withdrawal of
consent, adverse event, protocol violation, or lost to follow-
up, were censored at the time of discontinuation and were
assigned a last rank carried forward value for nonparametric
analyses of the efficacy end points.
The primary end point was compared between treatment
groups using the Fisher exact test. Exercise capacity end
points were compared between treatment groups using
nonparametric analysis of covariance, adjusting for center,
PAH etiology, and baseline peak VO2, 6-min walk distance,
Borg dyspnea score, and vasodilator use. Changes from
baseline in hemodynamic parameters were compared be-
tween treatment groups using parametric analysis of covari-
ance, adjusting for baseline value. For all efficacy end points,
the effects of covariates on the treatment effect, i.e., treat-
ment interactions, were further tested using logistic regres-
sion or parametric analysis of covariance. Covariates in-
cluded disease etiology, age, gender, race, and WHO class,
peak VO2 during exercise, walk distance, Borg score,
duration of disease, and vasodilator at baseline.
RESULTS
A total of 116 patients were included in this study: 60
received beraprost and 56 received placebo. The study was
prematurely terminated by the sponsor to accelerate assess-
ment of the study results. Fifty-six patients (93%) on
beraprost and 52 patients (93%) on placebo were included in
the 12-month evaluation; and 116 patients (100%) were
included in the 9-month evaluation per protocol. At the end
of 3, 6, 9, and 12 months, the mean dose of drug was 71 
3 g (n  60), 92  4 g (n  57), 98  6 g (n  49),
and 107  7 g (n  38), respectively, QID in the
beraprost group, and 83  4 g (n  53), 104  4 g (n
 47), 117  4 g (n  43), and 122  6 g (n  31),
respectively, QID in the placebo group.
Baseline characteristics. The placebo and beraprost
groups were well matched with respect to demographic and
baseline characteristics. The groups did not differ signifi-
cantly in PAH etiology, WHO class, peak VO2 during
exercise, 6-min walk distance, or severity of hemodynamics
(Table 1).
Disease progression. Patients treated with beraprost ex-
hibited less evidence of disease progression at six months (p
 0.002). This effect was not evident at either shorter or
Table 1. Demographic Characteristics at Baseline
Characteristic
BPS
(n  60)
Placebo
(n  56)
Age (yrs) 42  2 42  2
Race
White 73% 75%
Hispanic 10% 13%
African origin 7% 7%
Gender
Female 87% 84%
PAH
PPH 78% 70%
PAH–collagen vascular diseases 10% 11%
PAH–congenital systemic to
pulmonary shunts
12% 20%
WHO
Class II 55% 50%
Class III 45% 50%
Exercise
Exercise endurance–6-min walk (m) 433  11 445  10
Exercise tolerance–peak VO2 (ml/min) 955  48 892  40
Hemodynamics
RAPm (mm Hg) 8.3  0.7 8.8  0.6
PAPm (mm Hg) 56  2 55  2
PCWPm (mm Hg) 9  0.4 9  0.5
CI (l/min/m2) 2.7  0.1 2.4  0.1
PVRI (U·m2) 21  2 21  2
SBP (mm Hg) 120  2 119  2
SvO2 (%) 61  2 64  2
HR (beats/min) 78  1 79  2
Values are mean  SEM.
BPS  beraprost sodium; CI  cardiac index; HR  heart rate; PAH 
pulmonary arterial hypertension; PAPmmean pulmonary artery pressure; PCWPm
 mean pulmonary capillary wedge pressure; PPH  primary pulmonary hyperten-
sion; PVRI  pulmonary vascular resistance index; RAPm  mean right atrial
pressure; SBP  systolic systemic arterial pressure; SvO2  mixed venous oxygen
saturation; VO2  oxygen consumption; WHO  World Health Organization.
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longer follow-up intervals, although each component of this
end point occurred more frequently in the placebo group
than in the beraprost group throughout the study (Table 2).
Covariate analyses did not demonstrate any evidence of
treatment interactions.
Exercise capacity. CYCLE ERGOMETRY (EXERCISE TOLER-
ANCE). The peak VO2 during exercise at baseline and the
median change in peak VO2 during exercise at 3, 6, 9, and
12 months for the beraprost group and the placebo group
are shown in Table 3. Although the treatment effect did not
reach statistical significance at any time point, the direction
of change in the beraprost- versus placebo-treated patients
was in favor of beraprost and supportive of both the disease
progression data and the 6-min walk data. There was no
evidence of any treatment interactions when the effects of
covariates were assessed in the peak VO2 analyses.
6-MIN WALK TEST (EXERCISE ENDURANCE). The median
changes in distance walked in 6 min after 3, 6, 9, and 12
months in the beraprost group compared with the placebo
group are shown in Figure 1. The beraprost group walked
significantly further than the placebo group at month 3 and
6 (p 0.010 and p 0.016, respectively), but the difference
in 6-min walk was not significant at either month 9 or 12 (p
 0.098 and 0.180, respectively). The median difference
(Hodges-Lehmann estimate) in 6-min walk was 22, 31, 25,
and 23 m at month 3, 6, 9, and 12, respectively. From
analyses of the effects of covariates on the 6-min walk
distance results, evidence of treatment interaction was re-
markable in that patients with a shorter duration of PAH
had a larger treatment effect at month 3 (p  0.012), and
patients who had higher baseline Borg scores had a larger
treatment effect at month 9 (p  0.022).
For both the peak VO2 and 6-min walk data, the
outcome within the beraprost-treated patients did not
depend on the dose of beraprost with respect to the end
points assessed in this study.
Signs and symptoms. Borg dyspnea score was not signif-
icantly improved at any time point (Fig. 2). Dyspnea-
Fatigue Rating and composite Signs and Symptoms change
score were similarly unaffected (data not shown).
WHO functional class. At baseline, 55% of the beraprost-
treated patients and 50% of the placebo patients were class
II, with 45% of the beraprost and 50% of the placebo
patients class III. The majority of patients had no change in
WHO class over the course of the study, and although there
was no meaningful difference in the percentage of patients
who improved on beraprost compared with placebo treat-
ment during the 12-month study (Table 4), more of the
placebo patients worsened over the duration of the study
compared with the beraprost patients. Composite changes
in WHO class were significantly different in the beraprost
group at month 6 but not at other intervals.
Hemodynamics. The changes in hemodynamic measures
from baseline to month 12 are shown in Table 5. No
imputation was employed for missing data due to disease
progression or other reason for premature discontinuation.
The beraprost- and placebo-treated patients had small
variations in hemodynamic parameters, and no statistically
significant changes were detected.
Quality of life. Treatment with beraprost did not result in
significant improvement relative to placebo in global, phys-
ical, or emotional indices of quality of life (data not shown).
Safety and tolerability. The most frequent adverse events
in both treatment groups are shown in Table 6. Adverse
events characteristic of prostanoid effects, such as headache,
jaw pain, vasodilation (flushing), nausea, diarrhea, leg pain,
and foot pain were more common in patients treated with
beraprost. Palpitations were also significantly more common
in the beraprost group. Two patients (3%) in the beraprost
group (one before month 9 and one before month 12)
withdrew prematurely from the study owing to nausea. No
patients in the placebo group withdrew prematurely as a
result of adverse events. No clinically meaningful adverse
changes in hematologic or biochemical variables were seen
in the beraprost group. Serious adverse events (fatal, life-
threatening, or events requiring hospitalization) were more
common in the placebo group (25% of patients) than in the
beraprost group (18%) and were typical events (e.g., chest
pain, syncope) for this population of patients.
Table 3. Peak VO2 Changes from Baseline Through Month 12
Beraprost Placebo
Median
Difference* p Value†
Baseline 878 ml/min 777 ml/min — —
Month 3 3.8 (n  60) 36.3 (n  55) 35.4 0.125 (NS)
Month 6 5.8 (n  60) 54.3 (n  56) 39.6 0.204 (NS)
Month 9 39.7 (n  60) 108 (n  56) 57.0 0.160 (NS)
Month 12 68.8 (n  52) 156 (n  47) 66.0 0.084 (NS)
Median at baseline and median change from baseline. *Hodges-Lehmann estimate.
†Nonparametric analysis of covariance, adjusted for center, etiology of pulmonary
arterial hypertension, and baseline peak oxygen consumption (VO2) 6-min walk
distance, Borg dyspnea score, and vasodilator use.
Table 2. Cumulative Incidence of Disease Progression
BPS Placebo p Value*
Month 3 0/60 3/56 0.109 (NS)
Death 0 0
Rescue 0 2
2 VO2 0 1
Month 6 1/60 11/56 0.002
Death 0 2
Rescue 1 6
2 VO2 0 3
Month 9 8/60 15/56 0.102 (NS)
Death 1 2
Rescue 4 7
2 VO2 3 6
Month 12 10/56 15/52 0.254 (NS)
Death 1 2
Rescue 5 7
2 VO2 4 6
*Fisher exact test.
BPS  beraprost sodium; VO2  oxygen consumption.
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DISCUSSION
This double-blind, placebo-controlled study is the longest
controlled trial ever conducted in patients with PAH.
Originally planned for 12 months, the study was terminated
once all patients had completed 9 months of double-blind
therapy to accelerate data review. Although terminated
early, data were available for 93% of patients through 12
months of therapy. Patients treated with beraprost exhibited
less evidence of disease progression at 6 months, but this
effect was not evident at either shorter or longer follow-up
intervals. Similarly, beraprost-treated patients had improved
6-min walk distances at 3 and 6 months compared with
placebo, but not at either 9 or 12 months. The earlier time
point data are consistent with the findings of the recently
published Arterial Pulmonary Hypertension and Beraprost
European Trial (ALPHABET) Study (27) which demon-
strated that beraprost treatment for three months improved
exercise capacity in patients with PAH, particularly PPH
patients. However, unlike the ALPHABET Study, this
study did not demonstrate a relationship between etiology
(e.g., PPH vs. PAH related to other conditions) and effect
on exercise, nor did this study confirm the symptomatic
Figure 1. Median change in 6-min walking distance from baseline to months 3, 6, 9, and 12 in the placebo and beraprost sodium (BPS) groups; p  0.010
at 3 months; p  0.016 at 6 months; p  0.098 at 9 months; and p  0.180 at 12 months (adjusted for center, etiology, and baseline peak oxygen
consumption, 6-min walk, Borg dyspnea score, and vasodilator use). Worst rank for all missing data.
Figure 2. Mean change in Borg dyspnea score from baseline to months 3, 6, 9, and 12 in the placebo and beraprost sodium (BPS) groups; p  0.24 at
3 months; p  0.27 at 6 months; p  0.92 at 9 months; and p  0.75 at 12 months (analysis of covariance adjusted for center, etiology, and baseline peak
oxygen consumption, 6-min walk distance, Borg dyspnea score, and vasodilator use). Black bars  BPS; white bars  placebo. Number in the bars 
exact mean rates; lines  standard error of the mean.
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improvement in Borg dyspnea score. It is possible that
population differences explain these discordant findings as,
e.g., patients in the ALPHABET Study had a lower mean
baseline 6-min walk than patients in this study (approxi-
mately 370 m vs. approximately 440 m).
The results at early time points of this study are similar to
the results of Bosentan Randomized Trial of Endothelin
Antagonist Therapy (BREATHE)-1 (29) in which the
orally active dual endothelin receptor antagonist bosentan
(at the labeled dose of 125 g twice daily) was compared
with placebo over 16 weeks of therapy. As in the present
study, patients treated with active drug exhibited similar
improvement in 6-min walk (placebo-corrected mean dif-
ference of 35 m) and in the composite end point of “time to
clinical worsening” (defined as either the occurrence of
death, transplantation, initiation of chronic intravenous
epoprostenol rescue therapy, or hospitalization for PAH, p
 0.01), but no significant improvement in Borg dyspnea
score (p  0.42).
The data in the present trial suggest that the early
beneficial effects on disease progression and exercise char-
acteristics that may be observed with beraprost attenuate
with more prolonged exposure. It is possible that this
waning of effect may relate to a number of factors, includ-
ing: 1) inability to dose-escalate to maximal effects because
of intolerance to common side effects such as nausea,
headache, and/or dizziness; 2) lower potency of beraprost
relative to epoprostenol or other prostacyclin analogues; or
3) a suboptimal dose regimen relative to the elimination
half-life of beraprost (QID dosing with a half-life of only
approximately 1 h).
An important observation from this trial is that longer
controlled studies may be needed to evaluate the chronic
effects of therapeutic agents currently being used to treat
PAH (16,19,29) as well as for PAH therapies under clinical
investigation. This is particularly important given that
“surrogate” measures of efficacy, such as 6-min walk test
over three to four months of therapy, comprise the standard
historical evaluation that has been employed in clinical trials
to date for investigational agents in PAH. Only epoproste-
nol therapy has improved a non-surrogate end point, i.e.,
survival (4). It is possible that some treatment modalities,
such as chronic intravenous epoprostenol therapy, may
produce sustained benefit (possibly via pulmonary vascular
remodeling), whereas other therapies may yield only a small
or transient benefit that rapidly wanes with time. Although
even a short-term benefit may be desirable in patients with
Table 4. WHO Functional Class Changes (Percent) From
Baseline Through Month 12
Beraprost Placebo p Value*
Month 3 0.094 (NS)
Improved 10 11
No change 88 73
Worse 2 16
Month 6 0.039
Improved 15 9
No change 73 63
Worse 12 29
Month 9 0.804 (NS)
Improved 8 13
No change 65 57
Worse 27 30
Month 12 0.155 (NS)
Improved 10 11
No change 65 49
Worse 25 40
*Wilcoxon rank-sum test; drop-outs due to “disease progression” treated as “worse”.
WHO  World Health Organization.
Table 5. Hemodynamic Changes (Mean) From Baseline to Month 12
BPS Placebo p Value*
RAPm (mm Hg) 0  1 (n  38) 1  1 (n  28) 0.992 (NS)
PAPm (mm Hg) 1  1 (n  38) 2  2 (n  28) 0.664 (NS)
CI (l/min/m2) 0.1  0.1 (n  35) 0.1  0.2 (n  27) 0.875 (NS)
PVRI (mm Hg/l/min/m2) 1.1  0.9 (n  34) 2.5  0.9 (n  27) 0.253 (NS)
SvO2 (%) 2  3 (n  36) 3  3 (n  27) 0.424 (NS)
SBP (mm Hg) 1  3 (n  37) 5  3 (n  28) 0.360 (NS)
HR (beats/min) 1  1 (n  38) 1  2 (n  28) 0.623 (NS)
Values are mean  SEM. *Analysis of covariance, adjusted for baseline value.
Abbreviations as in Table 1.
Table 6. Most Frequent Adverse Events in the BPS and
Placebo Groups
Event
BPS
(n  60)
Placebo
(n  56) p Value
Headache 73% 57% 0.05
Jaw pain 57% 20% 0.0001
Vasodilatation 57% 27% 0.001
Nausea 47% 34% NS
Diarrhea 45% 27% 0.03
Dizziness 23% 30% NS
Pharyngitis 22% 30% NS
Abdominal pain 17% 20% NS
Chest pain 17% 16% NS
Asthenia 22% 7% 0.02
Other pain 27% 21% NS
Leg pain 18% 7% NS
Sinusitis 8% 18% NS
Back pain 13% 11% NS
Depression 13% 11% NS
Peripheral edema 13% 9% NS
Foot pain 13% 4% NS
Palpitations 12% 0% 0.008
Syncope 5% 14% NS
BPS  beraprost sodium.
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advanced disease, considerations of risk, side effects, and
expense must be addressed when assessing the clinical utility
of various agents to treat PAH.
CONCLUSIONS
In patients with PAH, beraprost increased time to disease
progression at six months, and improved exercise endurance
compared with placebo at three and six months. However,
these effects dissipated at 9 and 12 months of therapy and
were not associated with detectable benefit in symptomatic
status or quality of life as measured by standardized instru-
ments, nor with hemodynamic improvement. Because of
the potential convenience, relative safety, and economy of
an oral prostacyclin analogue, the quest for an effective
agent, particularly with an extended half-life, i.e., at least
4 h, remains a high priority. However, based on the data
from this study, longer studies may be needed to evaluate
overall risk:benefit considerations for many of the currently
used therapeutic agents in the treatment of PAH; these
long-term data are needed for safety as well as efficacy.
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